Seeport » MarketPlace
Advanced Search
Search Marketplace

MarketPlace

Biotechnology/Pharmaceutical Tags: Cancer treatment and diagnostics
IPC:C12P 021/08
NAICS:325414

Humanized Antibodies Against a New Adenocarcinoma Target

ImmVaRx, Inc.

  • Technology Description

    Labyrinthin is a unique and patented protein that has been identified on virtually all adenocarcinoma cell lines, tissues, and specimens and further constitutes a functional biomarker for detecting adenocarcinoma targets. Based on labyrinthin’s functional biomarker properties, ImmvaRx has isolated labyrinthin epitopes and their antibodies, which provide the basis for several types of diagnostics as well as therapeutics, such as a humanized anti-labyrinthin antibody, that work to target adenocarcinoma tumor cells and inhibit their growth.

  • Market Projection

    96?rand=353537
    2007 2008 2009 2010 2011
    Market Size $40000000000.0 $43000000000.0 $45000000000.0 $47000000000.0 $49000000000.0
    Market Share (%) 0.0% 0.0% 1.0% 5.0% 15.0%

  • Value Proposition

    A humanized anti-Labyrinthin antibody bypasses the need for patients to raise their own antibodies and, in addition to diagnostic applications, in itself would conceivably be a therapeutic agent (as one of several optional forms: efficacious alone, or conjugated to a radioactive or chemical cytotoxin). This technology would provide an advantage over other antibodies because it is not limited to a single cancer type, but rather the broad spectrum of adenocarcinomas, which constitute approximately 40% of all cancers. Moreover, this technology lowers the risk of collateral toxicity whereby healthy cells are not attacked by this antibody as it is exclusive to adenocarcinoma tumor cells.

  • Competitive Analysis

    95?rand=652669

  • Video Introduction

  • Commercialization Team

    • * Dr. Michael Babich, Vice President, ImmvaRx, Inc. 530-863-7463 michaelb@immvarx.com

      .

    • * Preferred point of Contact

  • Company Capsule

    ImmVaRx, Inc.

    ImmvaRx, Inc.
    3701 J Street, Sacramento, CA 95816

    916-455-3800
    http://www.immvarx.com

    ImmvaRx, Inc. is a biotechnology company focused on immunotherapeutics. The company, founded in 1999, is advancing two product platforms that address total annual markets exceeding $30 billion:

    • Humanized antibodies and vaccines for the diagnosis and treatment of adenocarcinoma cancers.
    • Treatment for a broad range of Type I allergies.
    ImmvaRx has established an efficient pipeline for synthesis and clinical testing of its therapies.

    Current capabilities, combined with external capital, will enable the company to complete Phase I and II clinical trials within three years demonstrating human efficacy for the treatment of adenocarcinomas, utilizing its proprietary humanized antibodies.

  • Documents

    Pdf Radosevich_US_Patent_-_Labyrinthin_sequence___Vaccine.pdf
    Pdf Radosevich_US_Patent_-_Labyrinthin_Gene___Antibodies.pdf